Table 1 Clinicopathological characteristics of the 23 included primary breast cancer samples (test cohort) and the 8 paired primary tumors and EDTA-treated bone metastases (validation cohort)
Feature | Grouping | Test cohort N=23 | Validation cohort N=8 | ||
|---|---|---|---|---|---|
N or value | % | N or value | % | ||
Age at diagnosis | Mean | 58.7 | 53.8 | ||
(in years) | Range | 40–89 | 43–63 | ||
Tumor size (in cm) | Mean | 3.5 | 3.8 | ||
Range | 1.4–14 | 1.8–10 | |||
Histological type | Invasive ductal | 14 | 61 | 4 | 50 |
Invasive lobular | 3 | 13 | 0 | 0 | |
Ductolobular | 3 | 13 | 3 | 38 | |
Other | 3 | 13 | 1 | 12 | |
Histological grade | I | 6 | 26 | 0 | 0 |
(Bloom and | II | 10 | 44 | 2 | 25 |
Richardson) | III | 7 | 30 | 2 | 25 |
Not available | 0 | 4 | 50 | ||
MAI (per 2 mm2) | Mean | 14.7 | 4.0 | ||
Range | 0–69 | 0–8 | |||
Lymph node status | Positive | 10 | 44 | 5 | 63 |
Negative | 9 | 39 | 2 | 25 | |
Not available | 4 | 17 | 1 | 12 | |
Molecular subtype | Luminal A | 20 | 87 | 6 | 75 |
Luminal B | 1 | 4 | 2 | 25 | |
Triple negative | 2 | 9 | 0 | 0 | |
HER2-driven | 0 | 0 | 0 | 0 | |
